GATA3 mediates doxorubicin resistance by inhibiting CYB5R2-catalyzed iron reduction in breast cancer cells

Zhen Zhu,Hongyu Shen,Jialin Xu,Zheng Fang,Guanqun Wo,Ying Ma,Kai Yang,Yalin Wang,Qiang Yu,Jin-hai Tang
DOI: https://doi.org/10.1016/j.drup.2023.100974
IF: 22.841
2023-05-11
Drug Resistance Updates
Abstract:Aims Neoadjuvant chemotherapy (NAC) is the primary preoperative therapy for breast cancer. The luminal subtype of breast cancer shows less NAC response than the basal subtype, with an inefficient NAC treatment effect. Thus, understanding the molecular and cellular mechanisms responsible for this chemoresistance is an important issue when determining optimal treatment. Methods Doxorubicin-induced apoptosis and ferroptosis was investigated using cytotoxicity, western blotting, and flow cytometry assays. The role of GATA3 in modulating doxorubicin-induced cell death was investigated both in vitro and in vivo . RNA-seq, qPCR, ChIP, and luciferase assay and association analyses were performed to validate the regulation of CYB5R2 by GATA3. The function of GATA3 and CYB5R2 in regulating doxorubicin-induced ferroptosis was evaluated with iron, ROS, and lipid peroxidation detection assays. Immunohistochemistry was performed for results validation. Results Doxorubicin-induced basal breast cancer cell death is dependent on iron-mediated ferroptosis. Overexpression of the luminal signature transcriptional factor GATA3 mediates doxorubicin resistance. GATA3 promotes cell viability by decreasing ferroptosis-related gene CYB5R2 expression and by maintaining iron homeostasis. Analyzing data from the public and our cohorts demonstrates that GATA3 and CYB5R2 are associated with NAC response. Conclusions GATA3 promotes doxorubicin resistance by inhibiting CYB5R2-mediated iron metabolism and ferroptosis. Therefore, patients with breast cancer who display high GATA3 expression do not benefit from doxorubicin-based NAC regimens.
pharmacology & pharmacy
What problem does this paper attempt to address?